Background: Staging of Hodgkin's disease (HD) is accomplished by a variety of invasive and non-invasive modalities. This prospective study was undertaken to investigate the value of whole-body positron emission tomography (PET) with 2-[
Introduction
Accurate anatomic staging of patients with newly diagnosed Hodgkin's disease (HD) is elementary in determining the appropriate treatment and predicting prognosis. Over the past twenty years, staging of HD has been mainly based on the Ann Arbor classification system which relies upon the spread of HD as determined by imaging methods and biopsies [1] . In addition to physical examination, routine staging procedures include plain film radiography, computed tomography (CT), lymphography, ultrasound (US), bone scanning (BS), bone marrow biopsy and biopsy of enlarged lymph nodes. In approximately one-third of patients initially presenting with apparently localised supradiaphragmatic disease by non-invasive methods, infradiaphragmatic involvement will be discovered when staging laparotomy is performed [2] . Staging laparotomy, which has been the gold standard for detecting infradiaphragmatic lesions in the past, has lost some of its importance, because of increased risk of second malignancies that may develop in patients who underwent splenectomy [3] . Bone marrow infiltration is seen in 5%-15% of patients with HD [4, 5] . A number of studies have demonstrated that knowledge of bone marrow involvement is meaningful for designing treatment procedures, especially in patients with early stage disease [6] . It must be borne in mind that bone marrow biopsy can give insight into a small sample of the total marrow volume only, which might not be of diagnostic significance because of the characteristically focal bone marrow involvement by HD. Magnetic resonance imaging (MRI) is useful for the detection of infradiaphragmatic lesions such as spleen-or liver involvement and bone marrow involvement [7] [8] [9] . However, MRI only visualizes a limited portion of the body; hence, it must be performed in areas which are clinically suspect, since 'whole-body' MRI is not applicable in a broad clinical setting. Gallium-67 scintigraphy is an established method in the treatment evaluation in lymphoma, especially for assessing the nature of a residual mass after treatment [10, 11] . However, it should be appreciated that the value of Gallium-67 scanning is not in the inital staging of patients with lymphoma [12] [13] [14] .
Positron emission tomography (PET) with 2-[
18 F]-fluoro-2-deoxy-D-glucose (FDG) produces images of regional tissue glycolytic activity. Malignant tissues exhibit increased rates of glycolysis. Whole-body FDG-PET generates tomographic images of the entire patient and show the distribution of FDG throughout the body. FDG-PET has been used in a number of studies evaluating malignant rymphomas [15] [16] [17] [18] . Recently we compared FDG-PET with CT for nodal staging in 27 patients with HD and could show that PET is more accurate for detecting nodal lymphoma than CT [18] . FDG-PET also showed a high potential in the detection of extranodal and bone marrow involvement too [19, 20] . To our knowledge there is only one study comparing FDG-PET as a screening method with conventional staging methods [21] . However, the number of patients with HD was relatively small. In this study we have compared the accuracy of FDG-PET with that of all conventional staging methods in order to identify lymphomatous lesions throughout the body in patients with newly diagnosed HD.
Patients and methods
Between 1992 and 1997 44 consecutive patients with newly diagnosed HD underwent whole-body FDG-PETas part of their staging work-up at the University of Ulm. Informed consent was obtained from all patients or guardians. Staging of the patients was based on the Ann Arbor classification [1] . FDG-PET was done within two weeks (mean) of physical examination, plain film radiography, CT, US, BS, bilateral bone marrow biopsy and histological confirmation by biopsy of an enlarged lymph nodes. In one of the patients lymphography was additionally performed as initial staging method. CT studies were performed of the neck, thorax, abdomen/pelvis, respectively. Incremental CT was performed with a conventional CT scanner (CT-Pace; GE Medical systems, Milwaukee, Wl) in 27 patients. Section thickness was five mm in the neck and ten mm in the chest, abdomen and pelvis. Nonionic contrast material was injected intravenously (200 ml iopamidol (612 mg iodine per mililiter), Solutrast 300; Byk Gulden, Constance, Germany) at a rate of 0.7 ml/sec with a power injector. Abdominal and pelvic scans were achieved 60 minutes after oral administration of contrast material (1000 ml of 2% L-lysinamidotrizoat, Peritrast; Kohler Chemie, Ansbach, Germany). Any lymphnode with diameter > 10 mm was considered as pathologic. Lymph nodes were also considered to be involved if other signs of malignancy such as pathologic contrast material enhancement or high number were encountered. In the remaining 17 patients spiral CT was performed with a double spiral CT scanner (120 KV, 200 mAS, section thickness 10 mm; ELCINT, Israel). In 27 patients biopsy of the liver was performed within the scope of the German Hodgkin's lymphoma study group for histopathological verification of liver involvement. Six patients underwent laparotomy as part of the staging. Posterior iliac crest biopsies were performed bilateral in all patients. Bone scanning was performed in 39 patients, US in 41 patients. Results of CT scans, US and bone scanning were evaluated by investigators without knowledge of the clinical or PET data.
FDG-PET was performed with an ECAT 931-08-12 scanner (Siemens-CTI, Knoxville, TN). Since October 1995, a Siemens-ECATExact HR+ Scanner was used. Patients received 240-360 (mean 270) MBq FDG intravenously. Patients received additionally 20 mg of furosemide intravenously to reduce artefacts in the renal collecting system. Static emission scans were obtained 50-60 minutes after injection of FDG. They fasted for at least six to eight hours prior to examination. Transmission scans were carried out prior to emission scans using a germanium-68/gallium-68 ring source. Acquisition time was 10 minutes per bed position. Images were obtained from the skull to the proximal femora. Images were reconstructed with an iterative Based on conventional staging methods.
reconstruction algorithm [22] . Qualitative evaluation was performed blinded and independently on sagittal, coronal, and transversal slices. FDG-uptake was classified according to intensity, size and shape. Any FDG-uptake that was not located in an area of physiologically uptake was considered suspicious for HD. A quantitative analysis of FDG uptake was not performed. PET images were interpreted by two investigators (F.M, S.N.R) without knowledge of the clinical status of the patient and the results of other imaging methods.
The following set of data were recorded for all patients: stage of HD after conventional staging methods; PET findings; stage of HD after PET and change of stage and disease management as a consequence of PETanalysis.
When FDG-PET yielded results that differed from those of standard methods, confirmation was ascertained by MRI of the skeleton in two cases, by lymphography in one case, by biopsy in five cases and by follow-up examination in two patients.
Results
The clinical characteristics of the 44 patients with HD are given in Table 1 . FDG-PET indicated FDG uptake at areas of documented active disease in 38 of 44 patients (86%). As a consequence of FDG-PET findings, stage of patients changed in six of 44 cases (12%). One patient was upstaged from stage I to II, three patients from stage II-IV, and another from stage III-IV. In the remaining patient a cervical lesion graded as positive at conventional staging methods was classified as negative by PET and stage changed from II to I. As a result of changing stage, treatment strategy had to be changed in each case. In four patients FDG-PET failed to identify sites of involved HD. In two of the patients a false positive PET result was obtained.
Nodal involvement
One-hundred twenty-eight of 133 diseased lymph node regions (96%) were identified as diseased by both routine staging procedures and FDG-PET (Table 2 ). In one patient PET failed to identify an axillary lymh node involvement. On account of radiological findings (size and pathological contrast) the lymph node was considered to be involved. The lymph node disappeared after therapy. In another patient CT showed an enlarged cervical lymph node, while PET was negative. Fine needle aspiration cytology revealed reactive lymph node without involvement of HD. In two patients PET showed increased FDG uptake at axillary lymphnodes. However, conventional staging methods like CT and ultrasound were negative at this site and results of FDG-PET were considered as false positive. Finally, in one case PET showed a pathologic FDG-uptake in an iliacal lymph node, while this region was not appreciated as involved by CT (Figure 1 ). Lymphography confirmed PET finding and showed an enlarged lymph node on the left iliacal region.
Extranodal involvement
In six of 44 patients with HD (14%) extranodal lesions were identified. Three of these six patients had involvement of the liver, three of the lung. Four were diagnosed by FDG-PET, whereas the remaining two were negative ( Table 3) . Comparison of FDG-PET and conventional methods revealed concordant findings in two patients. Five cases were verified by biopsy, another by follow-up examination. Patient 1 had several lesions in the lung, which were PET negative. These lesions were not verified by biopsy. No other reasons like a pulmonary infection could be found to explain these lesions. However, the lesions disappeared after therapy and were considered as involved. Patient 2 suffered from HD, subtype lymphocyte predominant. CT, US and PET were negative for liver involvement, whereas biopsy revealed infiltration with HD. In the third patient FDG-PET uncovered a lesion in the lung. This lesion was not visualized by CT (Figure 2) . The finding was histologically verified as being involved. In patient 4 and 5 lesions in the liver and in the lung were detected concordantly with PET and CT. They were both proven by biopsy. In patient 6 PET detected a Figure I . Images obtained in a 42-year-old patient (nodular sclerosis type) with focal FDG uptake, which indicates lymphomatous involvement in an ilical lymph node at transversal slices (a). The same lymph node is not depicted on contrast-enhanced CT scan. This lymphnode was confirmed as involved by lymphography (b). 
Bone marrow involvement
In 36 of 44 patients (82%) comparison of FDG-PETand conventional staging (bone marrow biopsy and bone scanning) revealed concordant negative findings for bone marrow and/or cortical bone involvement. Eight of 44 patients were positive concerning bone marrow and/or cortical bone involvement (Table 4 ). Seven of these eight patients were FDG-PET positive. Four of the eight patients suffered from the subtype nodular sclerosis, two of mixed cellularity, and two were not classifiable. Conventional staging and FDG-PET revealed concordant positive findings in five of eight cases. However, FDG-PET returned findings of cortical bone involvement in another two patients who were negative by conventional means. On the other hand only four bone marrow biopsies from the posterior iliac crest revealed bone marrow infiltration with HD. In only one patient FDG-PET failed to identify bone marrow infiltration, in which bone marrow biopsy showed an infiltration. Negative bone marrow biopsy and positive PET were revealed in all cases (four) by additional MRI, and results of PET were confirmed in all cases. In patient 7 additionally a guided biopsy was performed, which confirmed cortical bone infiltration. Bone scanning was positive in four of eight cases, in one patient bone scanning was not performed. In the four patients with negative bone marrow biopsy, FDG-PET visualized suspected uptake in the spine in all cases, which was confirmed by MRI in all cases. In patients with positive bone marrow biopsy FDG-PET revealed lesions at the iliaca crest in all cases, at the humerus in one case, polyfocal in the second and in the spine in an other case.
Discussion
The major goal in the staging of patients with HD is to detect all involved sites and to evaluate the extent of the disease. To solve this problem and to reach a rational investigation protocol a variety of different imaging tools and additional biopsies are used. However, the detection of infradiaphragmatic lesions and bone marrow involvement of HD by non-invasive methods remains a significant problem [2, 23] . CT scans, for example, are not very helpful in detecting infradiaphragmatic lesions due to their poor sensitivity (33%), specificity (76%) and accuracy (58%) [24] . The sensitivity of CT for the detection of liver involvement by HD ranges from 19% to 33% [25, 26] . Bilateral bone marrow biopsy still represents the established method for the evaluation of bone marrow involvement in patients with HD. However, infiltration of HD is characterized by focal occurence and a tendency for fibrosis [4] . Despite bilateral biopsy, the small sample volume makes this technique subject to sample error [23, 28] . Preliminary data indicate that MRI appears to be a sensitive technique for detection of infradiaphragmatic lesions and bone marrow involvement [7, 9] . However, MRI is usually performed in areas that are clinically suspect. There is only one study that has used 'whole-body' MRI for staging of patients with HD [27] . MRI findings in this study led to revised staging in 15% of patients. However, MRI in this study was compared only with chest radiography, bone marrow biopsy and lymphography. Only few patients underwent CT. 'Whole-body' MRI is not applicable in a broad clinical setting. The role of Gallium-67 scanning in the primary staging remains controversial [12] [13] [14] . Studies published so far revealed a potential limitation of Gallium-67 scanning in the staging of patients with lymphoma [14, 28] .
Recently we showed that FDG-PET is more accurate for detecting nodal and extranodal lymphoma in the primary staging of lymphoma patients compared with CT [18, 20] . PET not only showed all nodal involvement already seen at CT but additionally revealed lesions which let to a change in staging in 8% of patients [18] . Only two out of 194 lymph node regions were false positive. In the study dealing with extranodal involvement of lymphoma PET demonstrated a further 24 lesions compared with CT [20] . In 16% out of 81 patients staging was modified on the basis of FDG-PET. In another study we have investigated the role of FDG-PET in the detection of bone marrow involvement and PET has shown to be a sensitive tool for detecting bone marrow involvement [19] .
To the best of our knowledge, there is only one study presented that made use of whole-body FDG-PET and compared the results with all conventional staging methods [21] . However, only seven patients with HD underwent PET imaging in this study.
In the present study, PET has shown to be a sensitive tool in the staging of 44 patients with HD. Comparing our PET results with those obtained by conventional staging procedures important incremental data are achieved.
In 128 of 133 diseased lymph node regions (97%) FDG-PET and conventional staging methods were concordant in distinguishing presence or absence of disease.
For the detection of lymphomatous liver involvement, primary percutaneous needle biopsy of the liver is the gold standard, because staging laparotomy with surgical wedge biopsy of the liver and splenectomy has lost of its popularity because of increased development of secondary malignancies and complications of surgery [3, 30] . In our study, percutaneous liver biopsy was performed in 27 patients and staging laparotomy in another six patients with three positive results for lymphomatous liver involvement. FDG-PET was positive in two patients and failed to identify another patient with minimal liver involvement whereas 41 patients were negative. Putting these results into clinical perspectives, this noninvasive imaging method may be able to reduce invasive biopsy methods like staging laparotomy or percutaneous needle biopsy of the liver.
Bone scanning has recently shown its limited value in the clinical assessment of patients with untreated HD [31] . The FDG-PET assessment of bone marrow demonstrated a specificity of 100%, a sensitivity of 88%, a negative predictive value of 97% and a positive predictive value of 100%, respectively. In this study a false negative PET result occurred in only one patient. In this patient histology of bone marrow showed an unusually diffuse lymphomatous infiltration with HD. Without knowledge of the histopathological result of the lymph node, diagnosis of bone marrow involvement by HD would not be possible. In our study, FDG-PET has been shown to be a sensitive tool for the detection of bone marrow involvement in the central as well as peripheral skeleton. If FDG-PET revealed positive results for bone marrow involvement and bone marrow biopsy was negative, lymphomatous involvement was seen in the peripheral skeleton, especially in the spine. FDG-PET is both able to provide information of lymphomatous involvement not available by conventional staging methods and can give useful data otherwise detectable only utilizing invasive methods. This study has shown for the first time in a higher number of patients with HD, that FDG-PET can be used as a whole-body screening method for accurate staging. In our study, results obtained by FDG-PET are comparabale to those of conventional staging. However, PET also allowed detection of additional lesions and changed stages in six of 44 patients (14%). A limitation of this study is that not all positive FDG-PET results were confirmed by biopsy. This however, was not possible in all cases, depending on spread of HD throughout the body and the risk for the patients. Perhaps some positive PET results may be incorrectly interpreted as malignant. In conclusion FDG-PET scanning is a sensitive screening method in the staging of patients with HD. This whole-body screening method could reduce diagnostic requirements and complications within the scope of biopsies and may prove cost-effective compared with the sum of conventional staging methods. However, this new method is not available everywhere and the costs are very high compared to CTor MRI. These disadvantages may lower the acceptance of this new method. Therefore whole-body FDG-PET should be performed as a screening method prior to other investigations to plan a rational investigation protocol. Larger clinical studies are necessary to determine the full potential of whole-body FDG-PET in the scope of staging in patients with HD.
